The Filing Desk

Aquestive Therapeutics vs Ocular Therapeutix

Aquestive Therapeutics AQST · Ocular Therapeutix OCUL · Pharmaceuticals

Ocular Therapeutix reported revenue of $52 million in fiscal 2025, 1.2 times Aquestive Therapeutics' $44 million in fiscal 2025. Aquestive Therapeutics' revenue fell 22.6% in its latest year, and Ocular Therapeutix's fell 18.5%. Aquestive Therapeutics had an operating margin of -159.5%, against -519.8% at Ocular Therapeutix. Free cash flow was −$53 million at Aquestive Therapeutics and −$217 million at Ocular Therapeutix.

Side by side

Aquestive TherapeuticsOcular Therapeutix
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$44M$52M
Revenue growth−22.6%−18.5%
Revenue growth a year, last 5 years−0.6%24.5%
Gross margin58.4%87.3%
Operating margin−159.5%−519.8%
Net margin−188.1%−511.9%
Free cash flow−$53M−$217M
Free cash flow margin−119.0%−417.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count23.3%18.3%
Last close$3.91$6.21
P/E at the last close——
Insider trades, last 12 months—bought $461,354, sold $2.8 million
Piotroski F-score2 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Aquestive TherapeuticsOcular Therapeutix
Operating margin
Percent of revenue
Aquestive TherapeuticsOcular Therapeutix
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aquestive TherapeuticsOcular Therapeutix

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aquestive Therapeutics and Ocular Therapeutix pages.